Neuphoria Therapeutics IncNEUP
Price$3.51

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $15.6MTTM through 31 Mar 2026
Net Income -$17.5MTTM through 31 Mar 2026
Free Cash Flow -$17.2MTTM through 31 Mar 2026

Margins

Current
Gross Margin0.0%
EBITDA Margin-102.9%
Operating Margin-107.1%
Net Margin-111.6%

Returns

-62.9%ROE
-50.2%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio14.31x
Net Debt-$19.4Mnet cash position
Cash & Equivalents$19.4M

Quality Metrics

Altman Z-Score-5.71
Piotroski F-Score2 / 9
FCF Margin-109.6%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'25
FY2025: $15.6M
Diluted EPS-$7.90TTM
'23'24'25
FY2025: $-0.23

Dividend

No dividend

Capital Allocation

R&D Spend$9.9M
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.